Literature DB >> 26135947

Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling.

Jianjun Han1, Lu Zhang2, Hui Guo2, Weiya Z Wysham3, Dario R Roque3, Adam K Willson3, Xiugui Sheng4, Chunxiao Zhou5, Victoria L Bae-Jump6.   

Abstract

OBJECTIVES: Obesity and diabetes are well-known risk factors for the development of endometrial cancer. A high rate of aerobic glycolysis represents a key mechanism by which endometrial cancer cells consume glucose as its primary energy source. The up-regulated glycolytic pathway is a common therapeutic target whose inhibition has implications for anti-tumor activity in cancer cells. This study aimed to investigate the effect of various concentrations of glucose on cell proliferation in endometrial cancer.
METHODS: ECC-1 and Ishikawa cells were treated with low glucose (1mM), normal glucose (5mM) and high glucose (25mM), and cytotoxicity, apoptosis, cell cycle, adhesion/invasion, and changes of AMPK/mTOR/S6 and MAPK pathways were evaluated.
RESULTS: Our results revealed that high glucose increased cell growth and clonogenicity in two endometrial cancer cell lines in a dose dependent manner. Low glucose induced the activity of cleaved caspase 3 and caused cell cycle G1 arrest. High glucose increased the ability of adhesion and invasion by decreasing E-cadherin and increasing Snail expression. In addition, high glucose increased glucose uptake and glycolytic activity through modulating the AMPK/mTOR/S6 and MAPK pathways.
CONCLUSIONS: Our findings suggest that glucose stimulated cell proliferation through multiple complex signaling pathways. Targeting glucose metabolism may be a promising therapeutic strategy in the treatment of endometrial cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Glucose; Glycolysis; Invasion

Mesh:

Substances:

Year:  2015        PMID: 26135947      PMCID: PMC4672629          DOI: 10.1016/j.ygyno.2015.06.036

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  40 in total

Review 1.  Glucose metabolism disorders and the risk of cancer.

Authors:  Paweł Piątkiewicz; Anna Czech
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-03-30       Impact factor: 4.291

Review 2.  Molecular and pathologic aspects of endometrial carcinogenesis.

Authors:  Jonathan L Hecht; George L Mutter
Journal:  J Clin Oncol       Date:  2006-10-10       Impact factor: 44.544

3.  Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death.

Authors:  Hao Wu; Zonghui Ding; Danqing Hu; Feifei Sun; Chunyan Dai; Jiansheng Xie; Xun Hu
Journal:  J Pathol       Date:  2012-02-17       Impact factor: 7.996

4.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

Review 5.  Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship.

Authors:  Amanda Nickles Fader; Lucybeth Nieves Arriba; Heidi E Frasure; Vivian E von Gruenigen
Journal:  Gynecol Oncol       Date:  2009-04-29       Impact factor: 5.482

Review 6.  Obesity related hyperinsulinaemia and hyperglycaemia and cancer development.

Authors:  Susen Becker; Laure Dossus; Rudolf Kaaks
Journal:  Arch Physiol Biochem       Date:  2009-05       Impact factor: 4.076

7.  Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.

Authors:  Anna Krzeslak; Katarzyna Wojcik-Krowiranda; Ewa Forma; Paweł Jozwiak; Hanna Romanowicz; Andrzej Bienkiewicz; Magdalena Brys
Journal:  Pathol Oncol Res       Date:  2012-01-21       Impact factor: 3.201

8.  Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells.

Authors:  Xiaoyun Han; Xiugui Sheng; Hannah M Jones; Amanda L Jackson; Joshua Kilgore; Jessica E Stine; Monica N Schointuch; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  J Hematol Oncol       Date:  2015-01-29       Impact factor: 17.388

9.  D-Glucose-Induced Cytotoxic, Genotoxic, and Apoptotic Effects on Human Breast Adenocarcinoma (MCF-7) Cells.

Authors:  Christine K Tchounwou; Clement G Yedjou; Ibrahim Farah; Paul B Tchounwou
Journal:  J Cancer Sci Ther       Date:  2014

10.  Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.

Authors:  O V Leontieva; Z N Demidenko; M V Blagosklonny
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

View more
  62 in total

Review 1.  Emerging roles of aerobic glycolysis in breast cancer.

Authors:  Z Wu; J Wu; Q Zhao; S Fu; J Jin
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

Review 2.  Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression.

Authors:  Andréia Vasconcelos-Dos-Santos; Rafaela Muniz de Queiroz; Bruno da Costa Rodrigues; Adriane R Todeschini; Wagner B Dias
Journal:  J Bioenerg Biomembr       Date:  2018-01-11       Impact factor: 2.945

3.  Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment.

Authors:  Amanda de Barros Machado; Vania Dos Reis; Sebastian Weber; Julia Jauckus; Ilma Simoni Brum; Helena von Eye Corleta; Thomas Strowitzki; Edison Capp; Ariane Germeyer
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

4.  Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.

Authors:  Hui Guo; Weimin Kong; Lu Zhang; Jianjun Han; Leslie H Clark; Yajie Yin; Ziwei Fang; Wenchuan Sun; Jiandong Wang; Timothy P Gilliam; Douglas Lee; Liza Makowski; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 5.  Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?

Authors:  Juhong Yang; Reiko Nishihara; Xuehong Zhang; Shuji Ogino; Zhi Rong Qian
Journal:  J Diabetes Complications       Date:  2017-04-13       Impact factor: 2.852

Review 6.  Marine macroalga Caulerpa: role of its metabolites in modulating cancer signaling.

Authors:  Richa Mehra; Satej Bhushan; Felix Bast; Sandeep Singh
Journal:  Mol Biol Rep       Date:  2019-04-12       Impact factor: 2.316

7.  Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer.

Authors:  Haiyan Yang; Zhenguo Liu; Cuncun Yuan; Yunfei Zhao; Lei Wang; Jiong Hu; Dacheng Xie; Liwei Wang; Donghui Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Prognostic effects of glycometabolism changes in lung adenocarcinoma: a prospective observational study.

Authors:  Yiwei Huang; Xiaodong Yang; Fenghao Sun; Tao Lu; Guoshu Bi; Jiaqi Liang; Qihai Sui; Cheng Zhan; Yu Shi; Qun Wang
Journal:  Transl Lung Cancer Res       Date:  2019-12

9.  Investigation of glucose catabolism in hypoxic Mcf 7 breast cancer culture.

Authors:  İrem Bayar; Ayşegül Bildik
Journal:  Cytotechnology       Date:  2021-02-20       Impact factor: 2.058

Review 10.  High glucose: an emerging association between diabetes mellitus and cancer progression.

Authors:  Suangson Supabphol; Wunchana Seubwai; Sopit Wongkham; Charupong Saengboonmee
Journal:  J Mol Med (Berl)       Date:  2021-05-26       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.